Similar articles for PMID: 19292062

Year	Number of Results
1983	1
1984	1
1985	2
1986	4
1987	4
1988	4
1989	3
1990	3
1991	4
1992	4
1993	7
1994	7
1995	6
1996	9
1997	12
1998	11
1999	8
2000	4
2001	7
2002	5
2003	6
2004	3
2005	6
2006	4
2007	3
2008	9
2009	10
2010	10
2011	12
2012	8
2013	10
2014	14
2015	20
2016	15
2017	14
2018	19
2019	22
2020	24
2021	19
2022	11
2023	3
2024	0

1

[A clinical trial for homoharringtonine and low-dose cytosine arabinoside combined with G-CSF or GM-CSF to treat the relapsed or refractory acute myeloid leukemia (AML), geriatric AML and advanced myelodysplastic syndromes].

Xu J, Xu CG, Liu T, Xiang B, Chang H, He C. Xu J, et al. Sichuan Da Xue Xue Bao Yi Xue Ban. 2009 Jan;40(1):129-32. Sichuan Da Xue Xue Bao Yi Xue Ban. 2009. PMID: 19292062 Clinical Trial. Chinese.

2

Effect of low-dose cytarabine, homoharringtonine and granulocyte colony-stimulating factor priming regimen on patients with advanced myelodysplastic syndrome or acute myeloid leukemia transformed from myelodysplastic syndrome.

Wu L, Li X, Su J, Chang C, He Q, Zhang X, Xu L, Song L, Pu Q. Wu L, et al. Leuk Lymphoma. 2009 Sep;50(9):1461-7. doi: 10.1080/10428190903096719. Leuk Lymphoma. 2009. PMID: 19672772 Clinical Trial.

3

HAG (Homoharringtonine, Cytarabine, G-CSF) Regimen for the Treatment of Acute Myeloid Leukemia and Myelodysplastic Syndrome: A Meta-Analysis with 2,314 Participants.

Xie M, Jiang Q, Li L, Zhu J, Zhu L, Zhou D, Zheng Y, Yang X, Zhu M, Sun J, Xie W, Ye X. Xie M, et al. PLoS One. 2016 Oct 5;11(10):e0164238. doi: 10.1371/journal.pone.0164238. eCollection 2016. PLoS One. 2016. PMID: 27706258 Free PMC article.

4

[Efficacy of induction chemotherapy for patients with high-risk myelodysplastic syndrome (MDS) or MDS-transformed acute myeloid leukemia with CHG regimen and its comparison with regimen GAG and HA].

Su JY, Chang CK, Zhang X, Zhou LY, Song LQ, Xu L, Wu LY, He Q, Li X. Su JY, et al. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2009 Apr;17(2):459-63. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2009. PMID: 19379588 Clinical Trial. Chinese.

5

Low dose of homoharringtonine and cytarabine combined with granulocyte colony-stimulating factor priming on the outcome of relapsed or refractory acute myeloid leukemia.

Gu LF, Zhang WG, Wang FX, Cao XM, Chen YX, He AL, Liu J, Ma XR. Gu LF, et al. J Cancer Res Clin Oncol. 2011 Jun;137(6):997-1003. doi: 10.1007/s00432-010-0947-z. Epub 2010 Dec 9. J Cancer Res Clin Oncol. 2011. PMID: 21152934

6

Aclarubicin and low-dose Cytosine arabinoside in combination with granulocyte colony-stimulating factor in treating acute myeloid leukemia patients with relapsed or refractory disease and myelodysplastic syndrome: a multicenter study of 112 Chinese patients.

Li JM, Shen Y, Wu DP, Liang H, Jin J, Chen FY, Song YP, Song EY, Qiu XF, Hou M, Qiu ZC, Shen ZX. Li JM, et al. Int J Hematol. 2005 Jul;82(1):48-54. doi: 10.1532/IJH97.A10424. Int J Hematol. 2005. PMID: 16105759 Clinical Trial.

7

Combination chemotherapy with low-dose cytarabine, homoharringtonine, and granulocyte colony-stimulating factor priming in patients with relapsed or refractory acute myeloid leukemia.

Zhang WG, Wang FX, Chen YX, Cao XM, He AL, Liu J, Ma XR, Zhao WH, Liu SH, Wang JL. Zhang WG, et al. Am J Hematol. 2008 Mar;83(3):185-8. doi: 10.1002/ajh.20903. Am J Hematol. 2008. PMID: 17899614 Free article.

8

Efficacy and safety of CHG regimen (low-dose cytarabine, homoharringtonine with G-CSF priming) as induction chemotherapy for elderly patients with high-risk MDS or AML transformed from MDS.

Wu L, Li X, Su J, He Q, Zhang X, Chang C, Pu Q. Wu L, et al. J Cancer Res Clin Oncol. 2011 Oct;137(10):1563-9. doi: 10.1007/s00432-011-1020-2. Epub 2011 Aug 4. J Cancer Res Clin Oncol. 2011. PMID: 21845438

9

GM-CSF and low-dose cytosine arabinoside in high-risk, elderly patients with AML or MDS.

Winer ES, Miller KB, Chan GW. Winer ES, et al. Oncology (Williston Park). 2005 Apr;19(4 Suppl 2):11-4. Oncology (Williston Park). 2005. PMID: 15934494 Free article.

10

Epigenetic priming with decitabine followed by low dose idarubicin and cytarabine in acute myeloid leukemia evolving from myelodysplastic syndromes and higher-risk myelodysplastic syndromes: a prospective multicenter single-arm trial.

Zhou X, Mei C, Zhang J, Lu Y, Lan J, Lin S, Zhang Y, Kuang Y, Ren Y, Ma L, Wei J, Ye L, Xu W, Li K, Lu C, Jin J, Tong H. Zhou X, et al. Hematol Oncol. 2020 Oct;38(4):531-540. doi: 10.1002/hon.2755. Epub 2020 Jun 24. Hematol Oncol. 2020. PMID: 32469434

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

321 results

Results by year